Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study

NCT06785584 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

ALK-positive Advanced NSCLC
ALK-positive Non-small Cell Lung Cancer (NSCLC)
MPR
Neoadjuvant Therapy

Interventions

DRUG: Ensartinib

Sponsor

Fujian Medical University Union Hospital